4 drug(s) with this reaction
3,818 total reports
Epistaxis has been reported as an adverse reaction across 4 drug(s) manufactured by Haleon Us Holdings Llc in the FDA Adverse Event Reporting System (FAERS) database. A combined total of 3,818 adverse event reports mention epistaxis in connection with Haleon Us Holdings Llc products.
This page provides a breakdown of which Haleon Us Holdings Llc drugs are most commonly associated with epistaxis, along with report counts and links to detailed safety analyses for each medication. Understanding which drugs from a single manufacturer share a common adverse reaction can help patients and healthcare providers identify potential class-wide safety patterns.
The following Haleon Us Holdings Llc drugs have epistaxis listed in their FDA adverse event reports, sorted by report count:
In addition to epistaxis, the following adverse reactions have been reported across Haleon Us Holdings Llc's drug portfolio:
4 drug(s) manufactured by Haleon Us Holdings Llc have epistaxis listed in their FDA adverse event reports: FLUTICASONE PROPIONATE, ACETAMINOPHEN, CHLORPHENIRAMINE MALEATE, PHENYLEPHRINE HCL, IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE, SODIUM MONOFLUOROPHOSPHATE.
There are a combined 3,818 reports of epistaxis across 4 Haleon Us Holdings Llc drug(s) in the FDA adverse event database.